News
Why Is Repare Therapeutics Stock Trading Lower On Friday?
On Thursday, Repare Therapeutics Inc (NASDAQ: RPTX ) revealed data from its MYTHIC Phase 1 gynecologic expansion trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) for endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers .
As of the data cut-off date of November 14, 51 evaluable patients were enrolled in the gynecologic cancer expansion cohort of the MYTHIC trial.
Across all tumor types treated at the optimized RP2D (n=67), Lunre+Camo therapy showed a favorable and differentiated tolerability profile compared to current and emerging therapies.
The most common adverse event was anemia (26.9%, Grade 3).
Key Cohort Clinical Findings
Key efficacy outcomes from 27 evaluable patients with endometrial cancer show:
Key efficacy outcomes in 24 evaluable Platinum-Resistant Ovarian Cancer patients show:
Repare has consulted with the FDA and the European Medicines Agency, who have guided the company’s registrational development plans for Lunre+Camo in gynecologic tumors.
Repare plans to provide the final Phase 3 trial protocols for regulatory clearance imminently and intends to start the first Phase 3 Lunre+Camo trial in endometrial cancer in the second half of 2025.
Additionally, the company expects to initiate a small contribution of components trial in up to 40 patients with endometrial cancer in the first quarter of 2025.
Price Action: RPTX stock is down 52.4% at $1.89 at last check Friday.
Read Next:
Photo via Shutterstock.
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article Why Is Repare Therapeutics Stock Trading Lower On Friday? originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.